Company Performance - Dollar Tree Inc. shares fell more than 10% after its first-quarter 2025 earnings report, despite net sales increasing by 11.3% to $4.6 billion, surpassing both consensus and management guidance [2] - Same-store net sales rose by 5.4%, driven by a 2.5% increase in traffic and a 2.8% increase in average ticket, exceeding management's guidance of 3% – 5% [3] - Dollar Tree reported adjusted earnings of $1.26 per share, beating the analyst estimate of $1.21 and management expectation of $1.10 – $1.25 [3] Market Trends - Mullen Automotive, Inc. shares surged 191% to $15.69, indicating significant investor interest [9] - K Wave Media Ltd. shares increased by 124% to $4.3046 following a $500 million securities purchase agreement for a bitcoin-focused treasury strategy [9] - Cellectar Biosciences, Inc. shares rose 100% to $0.5581 after receiving FDA Breakthrough Therapy Designation for Iopofosine I-131 [9] - PTL Limited shares dropped 41% to $0.4300, while Raytech Holding Limited and ReShape Lifesciences Inc. saw declines of 27% and 23% respectively [9]

Group 1: Market Overview - U.S. stock futures are higher, with Nasdaq futures gaining approximately 700 points on Monday [1] Group 2: Orla Mining Ltd. Performance - Orla Mining reported adjusted earnings of 12 cents per share, exceeding market estimates of 10 cents per share [1] - The company's quarterly sales were $140.67 million, falling short of expectations of $163.19 million [1] - Orla Mining shares declined by 9.5% to $10.05 in pre-market trading following the sales miss [1] Group 3: Other Stocks in Pre-Market Trading - ReShape Lifesciences Inc. shares fell 22.7% to $5.15 after filing for a mixed shelf offering of up to $50 million [4] - Global IBO Group Ltd shares decreased by 20.1% to $5.58 after a significant gain of 102% on Friday [4] - Harmony Gold Mining Company Limited shares dropped 10.2% to $14.17 [4] - AngloGold Ashanti plc shares fell 10% to $40.30 after a 7% increase on Friday due to better-than-expected first-quarter results [4] - Seabridge Gold Inc. shares decreased by 9.4% to $11.38 [4] - Gold Fields Limited shares declined by 9.2% to $20.45 [4] - IAMGOLD Corporation shares dipped 8.7% to $6.40 [4] - Coeur Mining, Inc. shares fell 6.9% to $7.30 after a 12% gain on Friday [4] - Seabridge Gold Inc. shares also fell 6.6% to $11.79 [4]

Core Insights - ReShape Lifesciences has received a Notice of Allowance for a patent on its Diabetes Neuromodulation system, which utilizes vagus nerve modulation to treat Type 2 diabetes and hypoglycemia, with patent protection extending until August 4, 2037 [1][2] - The technology is designed to regulate blood glucose levels through targeted vagal nerve modulation, using a unique energy-efficient algorithm that consumes approximately 10 times less energy than traditional methods, allowing for smaller devices and longer battery life [2][3] - The company has completed preclinical development, demonstrating the system's efficacy in boosting insulin production and managing blood glucose levels, while remaining compatible with standard implantable pulse generators [2][3] Company Overview - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band systems and non-surgical options like the Obalon balloon technology [4] - The company is in the process of selling its assets, including the Lap-Band System and the Diabetes Neuromodulation system, to Biorad Medisys, which will take ownership of the DBSN™ system upon closing the transaction [5] Technology Details - The ReShape Diabetes Neuromodulation system is a minimally invasive implant that delivers bio-electronic neuromodulation to regulate plasma glucose by stimulating the pancreas and blocking signals to the liver [3] - The system is designed to be reversible and adjustable, potentially representing a significant advancement in personalized medicine compared to existing vagus nerve stimulation methods [3] Intellectual Property - The company holds a robust intellectual property portfolio with 63 issued or pending patents covering various aspects of its technology, including vagal neuromodulation and glucose regulation, which supports its commercialization efforts [2]

Core Insights - ReShape Lifesciences has entered an exclusive distribution agreement with Motion Informatics to import and distribute neuromuscular rehabilitation devices in the U.S. market [1][2] - The flagship product, Stimel-03, integrates Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES), and real-time electromyographic (EMG) biofeedback [2] - This partnership aims to enhance patient outcomes and expand the market reach of both companies in the neuromuscular rehabilitation sector [2][3] Company Overview - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band® System and investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system [4] - Motion Informatics focuses on next-generation neuromuscular rehabilitation, utilizing AI-driven neuroinformatics and augmented reality to create adaptive therapeutic platforms [3] - The collaboration positions both companies at the forefront of the neuromuscular rehabilitation market, aiming for global expansion and improved clinical care [2][3]

Core Insights - ReShape Lifesciences Inc. reported a significant reduction in overall operating expenses of 41.9% in 2024, excluding M&A related expenses, compared to 2023 [1] - The company entered into a definitive merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys, both of which are on track [1][3] - A strategic business update call is scheduled for April 10, 2025, to discuss these developments [1] Financial Performance - For the year ended December 31, 2024, ReShape reported revenue of $8.0 million, a decrease of 7.7% or $0.7 million compared to 2023 [8] - Gross profit for the same period was $5.1 million, down from $5.5 million in 2023, representing a decrease of 8.9% [9] - Operating expenses totaled $12.8 million in 2024, down from $20.9 million in 2023, reflecting significant cost-cutting measures [30] Expense Breakdown - Sales and marketing expenses decreased by 60.4% to approximately $3.0 million in 2024, primarily due to reduced advertising and marketing efforts [10] - General and administrative expenses fell by 32.9% to approximately $6.9 million, driven by reductions in legal, audit, and professional fees [11] - Research and development expenses decreased by 22.1% to $1.8 million, attributed to halted clinical trials and reduced consulting [12] Merger and Asset Sale - The merger with Vyome will result in ReShape being renamed Vyome Holdings, Inc., and the combined company will focus on immuno-inflammatory assets [3] - The asset purchase agreement with Biorad involves the sale of ReShape's key products, including the Lap-Band® System and Obalon® Gastric Balloon System [4] - The cash from the asset sale will contribute to determining post-merger ownership allocation between ReShape and Vyome stockholders [4] Patent Developments - In March 2025, ReShape received a Notice of Allowance for a patent related to its Diabetes Neuromodulation system, which will provide protection until April 12, 2039 [5] - An international patent was granted in February 2025 for the same technology, extending protection until December 4, 2039 [5] Market Position and Strategy - The company aims to expand access to its next-generation Lap-Band® 2.0 FLEX through a distribution agreement in Canada [7] - The introduction of GLP-1 pharmaceuticals in the U.S. has impacted revenue, despite a slight growth in units sold of the Lap-Band [8] - The strategic moves, including the merger and asset sale, are expected to create significant value and growth for shareholders [7]

As filed with the U.S. Securities and Exchange Commission on February 1, 2023 Registration Statement No. 333-269207 Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Primary Standard Industrial Classification Code Number) Delaware 3841 26-1828101 (I.R.S. Employ ...